Source:http://linkedlifedata.com/resource/pubmed/id/10491539
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1999-10-5
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0008-543X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
86
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1095-6
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:10491539-Anemia,
pubmed-meshheading:10491539-Antineoplastic Agents,
pubmed-meshheading:10491539-Cost-Benefit Analysis,
pubmed-meshheading:10491539-Erythropoietin,
pubmed-meshheading:10491539-Humans,
pubmed-meshheading:10491539-Neoplasms,
pubmed-meshheading:10491539-Recombinant Proteins
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
What are cancer patients willing to pay for prophylactic epoetin alfa?--A cost-benefit analysis.
|
| pubmed:publicationType |
Letter,
Comment
|